+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Hemophilia"

From
From
Hematology Collaboration and Licensing Deals 2016-2024 - Product Thumbnail Image

Hematology Collaboration and Licensing Deals 2016-2024

  • Report
  • October 2024
  • 100 Pages
  • Global
From
From
From
From
From
Hemophilia Market Report 2025 - Product Thumbnail Image

Hemophilia Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
From
From
Hemophilia B - Global Strategic Business Report - Product Thumbnail Image

Hemophilia B - Global Strategic Business Report

  • Report
  • March 2025
  • 188 Pages
  • Global
From
Rare Hematology - Global Strategic Business Report - Product Thumbnail Image

Rare Hematology - Global Strategic Business Report

  • Report
  • March 2025
  • 194 Pages
  • Global
From
Rare Hemophilia Factors - Global Strategic Business Report - Product Thumbnail Image

Rare Hemophilia Factors - Global Strategic Business Report

  • Report
  • March 2025
  • 93 Pages
  • Global
From
From
Bleeding Disorders Treatment Market Report 2025 - Product Thumbnail Image

Bleeding Disorders Treatment Market Report 2025

  • Report
  • January 2025
  • 200 Pages
  • Global
From
Bleeding Disorder Testing Market Report 2024 - Product Thumbnail Image

Bleeding Disorder Testing Market Report 2024

  • Report
  • September 2024
  • 175 Pages
  • Global
From
Loading Indicator

Hemophilia is a rare, inherited bleeding disorder in which the blood does not clot properly. People with hemophilia lack certain proteins, called clotting factors, which are necessary for normal blood clotting. Without these clotting factors, even a minor injury can cause excessive bleeding. Hemophilia is classified into two main types, hemophilia A and hemophilia B, depending on the clotting factor that is missing. The hemophilia market is a subset of the hematology market, which includes treatments for a variety of blood-related disorders. The hemophilia market is composed of treatments for hemophilia A and B, such as recombinant clotting factors, gene therapy, and other treatments. These treatments are used to reduce the frequency and severity of bleeding episodes, as well as to prevent bleeding in the first place. Some companies in the hemophilia market include Novo Nordisk, Pfizer, Shire, Bayer, and CSL Behring. Show Less Read more